Mosae Zorg Industries is focused on advancing a pipeline of host-directed therapies. Our initial development program is centered on our lead candidate, a revolutionary oral immunotherapy for patients suffering from a range of autoimmune disorders.

Lead Candidate: MZI-001

• Description: MZI-001 is a patented, 3D-printed, therapeutic chewing gum. It is a combination medical device and drug platform designed to restore innate immune function by neutralizing microbiome-produced methylmercury in the oral cavity. The gum acts locally and is a non-invasive, self-administered treatment.

• Indication: Autoimmune Disorders, with an initial focus on Multiple Sclerosis (MS), Systemic Lupus Erythematosus (SLE), and Rheumatoid Arthritis (RA).

• Mechanism: Toxin Interception & Innate Immune Preservation.

• Development Stage: Preclinical.

• Next Milestones: Completion of preclinical safety and efficacy studies, including advanced materials characterization via our CERIC-ERIC award, to support a formal application for clinical trials with the EMA and FDA.

For Patient-Focused Information
To learn more about the patient experience and the science behind our approach in an accessible format, please visit our patient resource site.